Institute has stably supplied an essential national medicine for 25 years, expanding treatment access for rare cancer patients

Cariemibgi (I-131 mIBG), a nationally designated essential medicine used to treat rare cancers including pediatric neuroblastoma. [Korea Atomic Energy Research Institute]
Cariemibgi (I-131 mIBG), a nationally designated essential medicine used to treat rare cancers including pediatric neuroblastoma. [Korea Atomic Energy Research Institute]

The Korea Atomic Energy Research Institute has been recognized for stably supplying a nationally designated essential medicine to more than 3,000 pediatric cancer patients. The institute developed and produces domestically a radiopharmaceutical that is difficult to manufacture in South Korea, expanding treatment access for patients with rare cancers.

The institute announced Thursday that its Radiopharmaceutical Support Center received a commendation from the Minister of Food and Drug Safety at the 40th National Pharmacy Day ceremony, held Wednesday at the Grand Mercure Ambassador Seoul Yongsan.

The award recognized the center's long-term stable supply of Cariemibgi (I-131 mIBG), a nationally designated essential medicine used to treat rare cancers such as pediatric neuroblastoma.

Cariemibgi is a therapeutic radiopharmaceutical that uses the radioactive isotope iodine-131. Its production requires specialized facilities for handling radioactive materials, strict safety management, and a pharmaceutical manufacturing and quality control system.

The small domestic patient population makes it difficult for private companies to sustain production, and the product's shelf life of just three days makes timely imports from abroad equally challenging.

To address these issues, the institute built an end-to-end domestic production system — from raw material manufacturing to finished drug production — using iodine-131 produced at its HANARO research reactor.

Through this system, the institute has supplied the medicine to more than 3,000 pediatric patients since 2001, supporting treatment for rare cancer patients.

To strengthen stable supply and quality control capabilities for radiopharmaceuticals, the institute formally launched the Radiopharmaceutical Support Center in 2024.

The center produces and supplies radiopharmaceuticals based on specialized personnel and production facilities that meet Good Manufacturing Practice standards.

The Radiopharmaceutical Support Center of the Korea Atomic Energy Research Institute receives a commendation from the Minister of Food and Drug Safety at the 40th National Pharmacy Day ceremony, held Wednesday at the Grand Mercure Ambassador Seoul Yongsan, in recognition of its long-term stable supply of Cariemibgi (I-131 mIBG). [Korea Atomic Energy Research Institute]
The Radiopharmaceutical Support Center of the Korea Atomic Energy Research Institute receives a commendation from the Minister of Food and Drug Safety at the 40th National Pharmacy Day ceremony, held Wednesday at the Grand Mercure Ambassador Seoul Yongsan, in recognition of its long-term stable supply of Cariemibgi (I-131 mIBG). [Korea Atomic Energy Research Institute]

In its first year of operation, the center became the first in South Korea to obtain product approval for iodine-131 as a radiopharmaceutical raw material, securing the foundation to produce and supply the substance domestically from raw ingredient to finished drug.

The center is now working to expand the supply of iodine-131 medicines while also building a production base for next-generation radioactive isotopes and radiopharmaceuticals, including terbium-161 (Tb-161).

"This award recognizes the institute's long-standing efforts to ensure a stable supply of essential medicines," said Jo Eun-ha, director of the Radiopharmaceutical Support Center. "We will continue to do our utmost to supply essential medicines and support the domestic radiopharmaceutical industry."

Jeong Yeong-uk, director of the HANARO Quantum Science Research Institute, said the establishment of a radiopharmaceutical production base is a core mission of the institute directly tied to public health. "We will actively support the center's growth as a key organization bridging public health and the related industrial ecosystem," Jeong said.


nbgkoo@heraldcorp.com